Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Daniel WolffCorey S CutlerStephanie J LeeIskra PusicHenrique BittencourtJennifer WhiteMehdi HamadaniSally AraiAmandeep SalhotraJose A Perez-SimonAmin AlousiHannah ChoeMi KwonArancha BermúdezInho KimGerard SociéSaurabh ChhabraVedran RadojcicTimothy O'TooleChuan TianPeter OrdentlichZachariah DeFilippCarrie L Kitkonull nullPublished in: The New England journal of medicine (2024)
Targeting CSF1R-dependent monocytes and macrophages with axatilimab resulted in a high incidence of response among patients with recurrent or refractory chronic GVHD. (Funded by Syndax Pharmaceuticals and Incyte; AGAVE-201 ClinicalTrials.gov number, NCT04710576.).